Articles tagged with: Drugs

BCI at the 59th ASH Annual Meeting

Posted in General News, Conferences, BCI on the Road Published by Reza Roozitalab 08 December 2017

"The most prestigious event in the haematology calendar"

BCI at the 59th ASH Annual Meeting

Research teams from our Centre for Haemato-Oncology have once again joined the world’s most influential figures in haematology to present their cutting-edge findings at the 59th ASH Annual Meeting & Exposition.

Hugh Brasher and Pancreatic Cancer UK Visit the BCI

Posted in General News, Engagement Published by Reza Roozitalab 10 November 2017

November is Pancreatic Cancer Awareness Month #PCAM

Hugh Brasher and Pancreatic Cancer UK Visit the BCI

Hugh Brasher and members of the team from Pancreatic Cancer UK visited the BCI to learn about the latest research and what is being done to beat pancreatic cancer sooner.

RECRUITING: ATOMIC-meso, a Global Randomised Trial of Triplet Drug Therapy for Malignant Mesothelioma

Posted in General News Published by Reza Roozitalab 19 October 2017

ADI-PEG20 continues to show promise

RECRUITING: ATOMIC-meso, a Global Randomised Trial of Triplet Drug Therapy for Malignant Mesothelioma

Several ongoing clinical trials, led by Dr Peter Szlosarek at the Barts Cancer Centre, continue to investigate the clinical efficacy of "arginine starvation" using ADI-PEG20...

Dr Peter Szlosarek at the 18th IASLC World Conference on Lung Cancer

Posted in Conferences, BCI on the Road Published by Reza Roozitalab 17 October 2017

ADI-PEG20 with Immune Checkpoint Blockade for Malignant Mesothelioma

Dr Peter Szlosarek at the 18th IASLC World Conference on Lung Cancer

Tomorrow, Wednesday 18th October, Dr Peter Szlosarek will present "Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma" at the 18th IASLC World Conference on Lung Cancer, Yokohama, Japan...

Encouraging results for a new mesothelioma chemotherapy

Posted in Publications Published by Zoe Leech 12 April 2017

Other hard-to-treat cancers are now being tested

Encouraging results for a new mesothelioma chemotherapy

A new publication from Dr Peter Szlosarek and his team in the Journal of Clinical Oncology marks the next step in the development of a revolutionary treatment for mesothelioma.

This cancer of the lung lining is hard to treat and an increasing problem as more people develop the condition...

Tactics to overcome mesothelioma treatment resistance

Posted in Publications Published by Zoe Leech 26 July 2016

Tactics to overcome mesothelioma treatment resistance

Pioneering work in our labs has led to a new "starvation" treatment strategy for mesothelioma, previously almost untreatable due to the difficulty of performing effective surgery and lack of available drugs.

Dr Sarah Martin has published new work on how mesothelioma could get around the attack with a view to preventing resistance and killing the cancer more efficiently...

Chemotherapy before surgery could boost ovarian cancer response to immunotherapy

Posted in In the Press, Publications Published by Zoe Leech 15 June 2016

New study published in Clinical Cancer Research by Prof Balkwill

Chemotherapy before surgery could boost ovarian cancer response to immunotherapy

Professor Fran Balkwill has published a study on ovarian cancer responses to treatment, which could mean hope for patients whose cancer has already spread.

The findings suggest that giving chemotherapy before surgery could improve tumour responses to immunotherapy given afterwards, by making the cancer cells more susceptible to immune attack by the immune system...

Vitamin A could boost pancreatic cancer chemotherapy

Posted in In the Press, Publications Published by Zoe Leech 25 May 2016

Vitamin A could boost pancreatic cancer chemotherapy

The latest study from the Kocher lab, published recently in the Journal of Pathology, has found that adding high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer.

This finding is now being taken forward in the clinical trial, STARPAC, by our Centre for Experimental Cancer Medicine.

FDA approves new bladder cancer treatment following BCI-led clinical trial

Posted in General News Published by Zoe Leech 20 May 2016

Tecentriq is the first PD-L1 inhibitor approved by the FDA

FDA approves new bladder cancer treatment following BCI-led clinical trial

Following a groundbreaking trial of a new bladder cancer treatment published in Nature in late 2014 and led by the BCI, the US Food and Drug Administration has now approved the immunotherapy for patients with advanced disease.

This is the first treatment advance for this cancer type in 3 decades and, now it has received first approval, should help many patients for whom existing treatments have not proved effective. European approval will hopefully follow.

Repurposing viruses to tackle pancreatic cancer drug resistance

Posted in Publications Published by Zoe Leech 15 April 2016

Repurposing viruses to tackle pancreatic cancer drug resistance

A new paper in the journal Oncotarget, led by Dr Gunnel Hallden, shows that viruses can be modified to force cancer cells to die, instead of evading apoptosis.

This also means they work better with existing anti-cancer drugs to destroy pancreatic tumours, a promising beginning to exploring more combination therapies to tackle the problem of drug resistance in pancreatic cancer...

[12 3 4 5  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.